Related content

CYP2C9 genetic variants and losartan oxidation in a Turkish population

By Babaoglu Melih   Yasar Umit   Sandberg Mia   Eliasson Erik   Dahl Marja-Liisa   Kayaalp S.   Bozkurt Atila  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 5, 2004-07 ,pp. : 337-342

Springer Publishing Company

Access to resources Recommend Favorite

The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/- Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments

By  

Current Drug Metabolism, Vol. 13, Iss. 9, 2012-11 ,pp. : 1303-1312

Bentham Science Publishers

Access to resources Recommend Favorite

Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population

By Gunes Arzu   Ozbey Gul   Vural Elif Hilal   Uluoglu Canan   Scordo Maria Gabriella   Zengil Hakan   Dahl Marja-Liisa  

Pharmacogenomics, Vol. 10, Iss. 5, 2009-05 ,pp. : 769-778

Future Medicine

Access to resources Recommend Favorite

CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers

By LLerena Adrian   Dorado Pedro   Ramírez Ronald   Calzadilla Luis R   Peñas-LLedó Eva   Álvarez Mayra   Naranjo María EG   González Idilio   Pérez Bárbaro  

Pharmacogenomics, Vol. 14, Iss. 16, 2013-12 ,pp. : 1973-1977

Future Medicine

Access to resources Recommend Favorite

Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

By Wennerholm Agneta   Nordmark Anna   Pihlsgård Maria   Mahindi Margarita   Bertilsson Leif   Gustafsson Lars  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 539-546

Springer Publishing Company

Access to resources Recommend Favorite